Axicabtagene ciloleucel
Gilead,Daiichi Sankyo
[]
 published data showing that even in pts receiving 3+ prior lines, autohct still led to a durable benefit (5 yr pfs 41% in pts who were in cr pre-autohct)
Assistant Professor of Medicine @UWCarbone | Lymphoma, Cellular Immunotherapies & BMT | Runner ????? Mother of 2 amazing. silly kids